Kedrion Biopharma is an Italian biopharmaceutical company that collects and fractionates human plasma in order to develop, produce and distribute plasma-derived medicines for the treatment of patients suffering from haemophilia, immunodeficiencies and other forms of serious diseases.
Kedrion focuses on people, giving great value to the well-being of those who benefit from its products, as well as to the communities and individuals with whom it operates and collaborates.
Kedrion is the bridge between donors and those in need of care, and operates globally to extend patient access to available therapies. Headquartered in Italy and with a commercial presence in 100 countries worldwide, it is the 5th world player and 1st in Italy in the plasma-derived products sector. Kedrion has over 2600 employees, of which more than 1100 are in Italy (850 in Tuscany): 37% are under 35, 50% are women.
Kedrion has five production plants: two in Tuscany (the Bolognana plant and the new plant in Castelvecchio Pascoli, nearing completion, both in the province of Lucca) and a plant in the province of Naples (in Sant'Antimo); abroad, one is in Hungary (in Gödöllő, near Budapest) and one in the United States (in Melville, in the State of New York).